Supplemental Reading for Chapter 1 Basic Principles of Clinical ...

view of its pharmacological properties, and therapeutic
efficacy in cerebral disorders. Drugs Aging
2:262, 1992.
205. Feigin VL, Rinkel GJ, Algra A, et al: Calcium antagonists
in patients with subarachnoid hemorrhage:
A systematic review. Neurology 50:876, 1998.
206. Gelmers HJ, Gorter K, DeWeerdt CJ, Wiezer HJA:
A controlled trial of nimodipine in acute ischemic
stroke. N Engl J Med 318:203, 1988.
207. Weinberger J, Terashita D: Drug therapy of neurovascular
disease. Heart Dis 1:163, 1999.
208. Steen PA, Gisvold SE, Milde JH, et al: Nimodipine
improves outcome when given after complete cerebral
ischemia in primates. Anesthesiology 62:406,
1985.
209. Trust Study Group: Randomised, double-blind,
placebo-controlled trial of nimodipine in acute
stroke. Lancet 336:1205, 1990.
210. The American Nimodipine Study Group: Clinical
trial of nimodipine in acute ischemic stroke. Stroke
23:3, 1992.
211. Meyer JS: Calcium channel blockers in the prophylactic
treatment of vascular headache. Ann Intern
Med 102:395, 1985.
212. Meyer JS, Hardenberg J: Clinical effectiveness of
calcium entry blockers in prophylactic treatment of
migraine and cluster headaches. Headache 23:266,
1983.
213. Morich FJ, Bieber F, Lewis JM, et al: Nimodipine in
the treatment of probable Alzheimers disease. Clin
Drug Invest 11:185, 1996.
214. Burger SK, Saul RF, Selhorst JB, et al: Transient
monocular blindness caused by vasospasm. N Engl
J Med 325:870, 1991.
215. Winterkorn JMS, Kupersmith MJ, Wirtschafter JD,
et al: Brief report: treatment of vasospastic amaurosis
fugax with calcium-channel blockers. N Engl J
Med 329:396, 1993.
216. Bartsch P, Maggiorini M, Ritter M, et al: Prevention
of high altitude pulmonary edema by nifedipine. N
Engl J Med 325:1284, 1991.
217. Coffman JD: Raynaud’s phenomenon. Hypertension
17:593, 1991.
218. Rodeheffer RJ, Rommer JA, Wigley F, et al: Controlled
double-blind trial of nifedipine in the treatment
of Raynaud’s phenomenon. N Engl J Med
308:880, 1983.
219. Raynaud’s Treatment Study Investigators: Comparison
of sustained-release nifedipine and temperature
biofeedback for treatment of primary
Raynaud phenomenon: results from a randomized
clinical trial with 1-year follow up. Arch Intern Med
160:1101, 2000.
220. Ram CV: Antiatherosclerotic and vasculoprotec-
References to Chapter 8 8-9
tive actions of calcium antagonists. Am J Cardiol
66:29I, 1990.
221. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, et al:
Retardation of angiographic progression of coronary
artery disease by nifedipine. Lancet 335:1109,
1990.
222. Waters D, Lesperance J, Francetich M, et al: A controlled
clinical trial to assess the effect of a calcium
channel blocker on the progression of coronary
atherosclerosis. Circulation 82:1940, 1990.
223. Motro M, Shemesh J: Calcium channel blocker
nifedipine slows down progression of coronary calcification
in hypertensive patients compared with
diuretics. Hypertension 37:1410, 2001.
224. Mason RP: Mechanisms of atherosclerotic plaque
stabilization for a lipophilic calciumantagonist amlodipine.
Am J Cardiol 88 (Suppl): 2M, 2001.
225. Pitt B, Byington RP, Furberg CD, et al: Effect of
amlodipine on the progression of atherosclerosis
and the occurrence of clinical events. Circulation
102:1503, 2000.
226. Mason RP: Scientific rationale for combination of
a calcium channel antagonist and an HMG-CoA
reductase inhibitor. A new approach to risk factor
management. Drugs 68: 885, 2008.
227. Schroeder JS, Gao S-Z, Alderman EL, et al: A preliminary
study of diltiazem in the prevention of
coronary artery disease in heart transplant recipients.
N Engl J Med 328:164, 1993.
228. Borhani NO, Mercuri M, Borhani PA, et al: Final
outcome results of the multicenter isradipine
diuretic atherosclerosis study (MIDAS). JAMA
276:785, 1996.
229. Einecke D: ELSA studies progression of atherosclerosis:
Calcium antagonist arrests the process more
than a beta blocker. MMW Fortschr Med 143:6,
2001.
230. Schwartz ML, Rotmensch HH, Frishman WH,
Vlasses P: Potential applications of calcium-channel
antagonists in the management of noncardiac
disorders. In: Packer M, Frishman WH, eds.
Calcium Channel Antagonists in Cardiovascular
Disease. Norwalk, CT: Appleton-Century-Crofts,
1984:371–382.
231. Cristakis GT, Fremes SE, Weisel RD, et al: Diltiazem
cardioplegia: A balance of risk and benefit. J
Thorac Cardiovasc Surg 91:647, 1986.
232. Seitelberger R, Zwolfer W, Huber S, et al: Nifedipine
reduces the incidence of myocardial infarction
and transient ischemia in patients undergoing coronary
bypass grafting. Circulation 83:460, 1991.
233. Piessens J, Brzostek T, Stammen F, et al: Effect of intravenous
diltiazem on myocadial ischemia during
percutaneous transluminal coronary angioplasty.